{"id":970260,"date":"2026-06-03T15:57:57","date_gmt":"2026-06-03T19:57:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/"},"modified":"2026-06-03T15:57:57","modified_gmt":"2026-06-03T19:57:57","slug":"grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/","title":{"rendered":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc."},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, June  03, 2026  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Grace Therapeutics, Inc. (\u201cGrace Therapeutics\u201d or the \u201cCompany\u201d) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (\u201cCRL\u201d) for the Company\u2019s New Drug Application for GTx-104 revealing that the CRL referenced certain items \u201crelated to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.\u201d The price of the Company\u2019s stock dropped following this news.<\/p>\n<p align=\"justify\">If you purchased Grace Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LEsiuw6zbqz2MnnSrbNXeBdRLMH80T3v4QlWC2slg7dzOdAZLj9LIebAK6-pz5c-1cTvOdeg9_GgOuBnPSO-cno8d14nD9HpWYM0lxobAy0=\" rel=\"nofollow\" target=\"_blank\"><u>cholzer@holzerlaw.com<\/u><\/a> or Joshua Karr, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C5D-EwYoam628kBdU4g8pTo4ULjC6A7PDwkiMOkbKPW2MNp0dfeZHVn24zd9wT1kvKmxwkkDbTiSaCAOPj5D7bxk554T-ERAcJw_9kghx84=\" rel=\"nofollow\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lET4XysAtDkj0Av6sk8QPl8RnMh1LvpocZ-x1uumZFdKYlZyYu_i51p1p4nECa6qw36ROP0-v0okGYoo41MdOTCEAe3xxwTmyR1mKtV2JPG66Y5nMaYRsQgnGHH_bXNhNlUxH1Rozy0wj7H1gujgretrl0JgGyx9QD0PEB6cMFM=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/grace-therapeutics\/<\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website,\u202fwww.holzerlaw.com,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f\u00a0<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.\u00a0<br \/>(888) 508-6832 (toll-free)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LEsiuw6zbqz2MnnSrbNXeBdRLMH80T3v4QlWC2slg7dcSoLrfUgEiR6v7aCC2IyegFm1q11m74PM-ePGgwvFUsB5itrSY7BsPYDuMbPkcVs=\" rel=\"nofollow\" target=\"_blank\"><u>cholzer@holzerlaw.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmEwMWRlMjYtNDRhOC00MjA1LWEzMWItMGQ3MDA5MGI3NjZiLTExOTIzMzYtMjAyNi0wNi0wMy1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Grace Therapeutics, Inc. (\u201cGrace Therapeutics\u201d or the \u201cCompany\u201d) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (\u201cCRL\u201d) for the Company\u2019s New Drug Application for GTx-104 revealing that the CRL referenced certain items \u201crelated to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.\u201d The price of the Company\u2019s stock dropped following this news. If you purchased Grace Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970260","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Grace Therapeutics, Inc. (\u201cGrace Therapeutics\u201d or the \u201cCompany\u201d) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (\u201cCRL\u201d) for the Company\u2019s New Drug Application for GTx-104 revealing that the CRL referenced certain items \u201crelated to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.\u201d The price of the Company\u2019s stock dropped following this news. If you purchased Grace Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our &hellip; Continue reading &quot;GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T19:57:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.\",\"datePublished\":\"2026-06-03T19:57:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/\",\"name\":\"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\",\"datePublished\":\"2026-06-03T19:57:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/","og_locale":"en_US","og_type":"article","og_title":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk","og_description":"ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Grace Therapeutics, Inc. (\u201cGrace Therapeutics\u201d or the \u201cCompany\u201d) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (\u201cCRL\u201d) for the Company\u2019s New Drug Application for GTx-104 revealing that the CRL referenced certain items \u201crelated to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.\u201d The price of the Company\u2019s stock dropped following this news. If you purchased Grace Therapeutics stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our &hellip; Continue reading \"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-03T19:57:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc.","datePublished":"2026-06-03T19:57:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/","name":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=","datePublished":"2026-06-03T19:57:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTQ5MiM3NjM1NjUxIzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grce-investor-alert-holzer-holzer-llc-investigation-of-grace-therapeutics-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRCE INVESTOR ALERT: Holzer &amp; Holzer, LLC Investigation of Grace Therapeutics, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970260"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970260\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}